Immucell (ICCC) Liabilities and Shareholders Equity (2010 - 2026)

Immucell (ICCC) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $46.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 9.63% year-over-year to $46.6 million; the trailing twelve-month figure through Jun 2026 stood at $177.4 million (changed 0.16% YoY), and the FY2025 full-year result was $42.5 million, down 5.69% from the prior year.
• Liabilities and Shareholders Equity climbed to $46.6 million in Q2 2026 per ICCC's latest filing, from $42.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $46.7 million in Q1 2022 and bottomed at $41.9 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $44.5 million across 5 years, with a median of $44.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity advanced 17.86% in 2022, then decreased 7.66% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $44.9 million in 2022, then decreased by 2.35% to $43.8 million in 2023, then grew by 2.95% to $45.1 million in 2024, then fell by 5.69% to $42.5 million in 2025, then advanced by 9.63% to $46.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $46.6 million, $42.5 million, and $45.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.